Subsequent studies further showed that combined dabrafenib and trametinib, compared with BRAF inhibition alone, led to long-term benefits, delayed the emergence of resistance and reduced toxic effects in patients who had melanoma with the BRAF mutation [109,110,111,112]. Here, BRAF is linked to melanoma.